For example, CCR7 identifies central memory T (TCM) cells that home to secondary lymphoid organs, and distinguish them from effector memory T (TEM) cells that home to peripheral nonlymphoid tissues [9]. CXCR3 and CCR5 are preferentially expressed on IFN-γ-producing Th1 cells, while CCR3, CCR4, and CRTH2 are preferentially expressed on subsets of Th2 cells that produce IL-4, IL-5, and IL-13 [10]. The Th1- and Th2-specifying transcription factors T-bet and GATA3 directly control CXCR3 and CCR3 gene transcription, respectively [11, 12], thus providing a molecular mechanism for the coregulation

of effector function and migratory capacity. The discovery of Th17 cells in mice prompted us to search for chemokine receptors distinctive of this
age in humans. By analyzing the cytokine-producing capacities of freshly

isolated human CD4+ memory T-cell subsets expressing different chemokine receptors, find more it was found that both in the peripheral blood of healthy donors and in the synovial fluid of rheumatoid arthritis patients the CCR6+ subset contained all IL-17-producing T cells expressing RORC mRNA [13], the human ortholog of mouse RORγt. Remarkably, when the proliferative T-cell response to BGB324 nmr Candida albicans recall antigens was analyzed, the CCR6+ subset, in particular the fraction coexpressing CCR4, was found to contain the vast majority of antigen-specific memory T cells; furthermore, while proliferating, these cells also produced high amounts of IL-17 [13]. Taken together, these findings provided a convenient marker for the identification of the human counterpart of mouse Th17 cells, and suggested that CCR6 expression is part of the Th17-cell differentiation program. They also suggested, for the first time, that Th17 cells are involved in the host-response to fungi. This notion was subsequently corroborated by the finding that patients with defects in the Th17 pathway suffer from

severe infections by fungi and extracellular bacteria such as C. albicans and Staphylococcus aureus, respectively [14, 15]. Annunziato et al. provided further evidence supporting CCR6 expression as an important component of human Th17-cell differentiation when they isolated human Th17 clones from the peripheral Gemcitabine blood, tonsils, and small intestine of patients with Crohn’s disease and found that these clones expressed CCR6, RORγt, and IL-23R [16]. Interestingly, T cells isolated from inflamed tissue samples simultaneously produced IL-17 and IFN-γ and coexpressed T-bet and RORγt, demonstrating the existence of cells exhibiting a hybrid Th17/Th1 phenotype. When exposed to IL-12, these cells downregulated RORγt and ceased to produce IL-17, while maintaining IFN-γ production. In addition, Farber et al. described a subset of CD8+ T cells expressing CCR6 and producing IL-17 [17] and Dieli et al. found that CCR6+ Vγ9Vδ2 T cells produced IL-17 but neither IL-22 nor IFN-γ [18].